Navigation Links
Opexa Presents Tovaxin Research at Federation of Clinical,Immunology Societies Annual Meeting

Jim Williams, PhD, chief operating officer.

About T-cell Vaccination

For a T-cell vaccine to be effective, it should be able to induce T-cell cytotoxic and/or regulatory immune responses against the pathogenic T-cells. Studies of T-cell vaccine have indicated that T-cell vaccination with peripheral blood-derived autologous myelin-peptide selected T-cells in multiple sclerosis patients resulted in the in vivo induction of CD8+ cytotoxic T-cells and CD4+CD25+FoxP3 Tregs specific for T-cell vaccine. The induction of anti-idiotypic cytotoxic CD8+ effector T-cells and anti-ergotypic CD4+CD25+FoxP3 positive Tregs is believed to provide a therapeutically effective dual mechanism of protection to patients treated with Tovaxin(TM). The observed regulatory immune responses have been shown to collectively correlate with clinical improvement in treated patients.

About TERMS

The Tovaxin Phase IIb clinical study will include 150 patients in a multicenter, randomized, double blind, placebo-controlled trial designed primarily to evaluate the efficacy, safety and tolerability of the Tovaxin T Cell vaccination with clinically isolated syndrome (CIS) and relapsing-remitting MS (RR-MS) patients. A total of 100 patients will receive Tovaxin, while 50 will receive placebo. The study is designed as a two-arm, 52-week, parallel-group study, whereby patients will be given five subcutaneous injections at 0, 4, 8, 12 and 24 weeks. The analyses will be performed at the end of the 52-week study to assess the safety and efficacy of Tovaxin. The primary efficacy variable is the cumulative number of gadolinium-enhancing lesions on T1-weighted MRI scans summed over the Week 28, 36, 44, and 52 MRIs. The secondary efficacy variables are the cumulative number of new gadolinium-enhancing lesions at Weeks 28-52, the change in T2-weighted lesion volume, and the annualized relapse rate.

All patients who complete the trial will be eligible to participate in an optional o
'"/>




Page: 1 2 3 4

Related medicine technology :

1. Opexa Advances Monocyte Derived Islet Technology to Proof of Principle in stz-induced NOD/SCID Mice
2. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Extension Trial with Tovaxin for Multiple Sclerosis
3. Opexa Therapeutics Reports Positive Top-line Data in Phase I/II Dose Escalation Trial with Tovaxin for Multiple Sclerosis
4. Inspiration Biopharmaceuticals Presents Data From Hemophilia Program at International Society On Thrombosis and Haemostasis (ISTH) Annual Meeting
5. European Society for Medical Oncology (ESMO) Presents Data from the Clinical Trial of MediGenes Cancer-Killing Virus in Press Conference
6. Cytogen Presents Phase 1 Data Showing Promising Antitumor Activity and Safety Profile of Quadramet at International Myeloma Workshop
7. SemBioSys Presents Positive Insulin Data at the American Diabetes Association Conference
8. Tranzyme Pharma Presents Initial Phase IIa Data for its Novel Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis
9. Novagali Pharma Presents at AACO the Results of its Pivotal Phase III Clinical Trial of Vekacia in Children Suffering From Vernal Keratoconjunctivitis
10. BioLife Solutions Presents Data on CryoStor at International Society for Cellular Therapy Annual Meeting
11. Genaera Presents Preclinical Data on Trodusquemine (MSI-1436) for the Treatment of Obesity at the American Diabetes Association 67th Scientific Session
Post Your Comments:
(Date:3/30/2015)... Calif. , March 30, 2015  The investigational ... agent to alleviate certain menopause symptoms, such as hot ... March Journal of Women,s Health .[i] ... S- equol for menopausal vasomotor symptoms and possibly ... supporting safety of S- equol, physicians and health ...
(Date:3/30/2015)... Mar. 26, 2015 Research and Markets ... the addition of the "Urological Catheters ... to their offering. This report ... in Thousand Units and US$ Thousands by ... Catheters, & Peritoneal Catheters), and Urinary Catheters ...
(Date:3/30/2015)... 2015 Research and Markets ( ... "Marine Biotechnology - Global Strategic Business Report" ... estimates and forecasts are provided for the period ... is provided for these markets. Market data and ... This report analyzes the worldwide markets ...
Breaking Medicine Technology:New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 2New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 3New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 4New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 5New Scientific Review Suggests Some Women May Benefit from Considering Use of S-equol to Ease Menopause Symptoms 6Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 2Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 3Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 4Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 5Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 6Urological Catheters - Global Strategic Business Report 2015-2020: Burgeoning Ageing Populace to Propel Catheter Usage 7Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 2Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 3Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 4Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 5Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 6Marine Biotechnology - Global Strategic Business Report 2015-2020: Polysaccharides from Marine Microalgae Holds Tremendous Potential 7
... Pharmaceuticals, Inc. (Nasdaq: MAPP ) today announced completion ... has now completed the final trial necessary to support a ... an NDA in the first half of 2011.  LEVADEX is ... 3 clinical development for the acute treatment of migraine. ...
... 21, 2010 Bellicum Pharmaceuticals, Inc. today announced $3 ... be used to prepare for Phase II trials of ... prostate cancer (mCRPC), and CaspaCIDe™, a cell therapy safety ... therapy (HSCT) setting. The new funding brings ...
Cached Medicine Technology:MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial 2MAP Pharmaceuticals Announces Completion of LEVADEX™ Open-Label Safety Trial 3Bellicum Pharmaceuticals Announces $3 Million in Convertible Note Funding 2
(Date:3/30/2015)... FMC Corporation’s Health and Nutrition division ... Epax® Ultra and Core concentrates manufactured in the ... ensures the manufacturing process and all physical raw ... for Halal. , The new Halal certification ... advance its customer service to a global market ...
(Date:3/30/2015)... CA (PRWEB) March 30, 2015 On ... blue polo for yellow to inspire courage in Seth ... from Severe Combined Immunodeficiency (SCID). SCID causes affected individuals ... marrow transplant is needed to allow the development of ... transplant last Friday, created a video with his family ...
(Date:3/30/2015)... GenSight ®, provider of an ... a leader in The Forrester Wave™: Strategic Planning For ... The independent report positions GenSight as a leader and ... of 5) for the analytics, corporate strategy, assessment, direction ... GenSight’s position in the Leaders category. , According to ...
(Date:3/30/2015)... York, NY (PRWEB) March 30, 2015 V/NO ... that includes a convenient flute for opening/closing and for reuse. ... wine on the go. Health-conscious New Yorkers, professionals, and basically ... is sophisticated yet delicious to kick back socially or pair ... arise. , “ V/NO is dealcoholized wine and that ...
(Date:3/30/2015)... The “Orthopedic Software Market [By ... By Applications (Orthopedic Surgery, Joint Replacement, Fracture ... – Global Forecast to 2020” analyzes and ... in North America, Europe, Asia-Pacific and the ... before Buying: http://www.marketsandmarkets.com/Enquiry_Before_Buying.asp?id=94720371 , This ...
Breaking Medicine News(10 mins):Health News:FMC Health and Nutrition Announces Halal Certification for Epax® Brand Omega-3 Ingredients 2Health News:24Hr HomeCare Staff Hosts #WearYellowForSeth Campaign for Five-Year-Old Boy with Severe Combined Immunodeficiency 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 2Health News:GenSight Named as a Leader by Independent Research Firm in the Strategic Planning Market 3Health News:Napa Valley Alcohol-Removed Red, White & Rosé Wines Have Launched. 2Health News:The Global Orthopedic Software Market is Expected to Reach $308.5 Million by 2020 – Report Published by MarketsandMarkets 2Health News:The Global Orthopedic Software Market is Expected to Reach $308.5 Million by 2020 – Report Published by MarketsandMarkets 3Health News:The Global Orthopedic Software Market is Expected to Reach $308.5 Million by 2020 – Report Published by MarketsandMarkets 4
... Fund and Sustain to Raise ... Donations after Floods, ... the decimation of a number of organic and family farms,in Minnesota ... farmers, nonprofits, restaurants and natural,food cooperatives to implement a multifaceted, region-wide ...
... Meeting Expectations today announced,that it has been ... of the industry,s,largest and most influential full-service independent ... corporate market. Compiled by,Penton Media,s Corporate Meetings & ... billion corporate meetings and events,industry, the CMI 25 ...
... of us have never heard of immune infertility, yet ... Immune infertility is one of 80 autoimmune disorders, a ... Type 1 Diabetes. This reproductive disorder affects both men ... on sperm. , A recent discovery at the University ...
... N.J., Sept. 12 Leaders of the,medical community ... association to address increasing concerns that the quality ... of the practice of medicine, are,in jeopardy. ... was,created to provide a strong, unified voice for ...
... Medina General Hospital and,University Hospitals announced today ... which Medina General has indicated its desire to ... network of,community- based hospitals. The agreement is subject ... regulatory and governance approvals. "We,re excited about ...
... joins Growing Company, METAIRIE, La., Sept. 12 ... orthodontic and dental practices,worldwide, has hired David Ward ... experience will be invaluable to serving our existing,doctors ... of our,company," said Chris Roussos, president and CEO ...
Cached Medicine News:Health News:Whole Foods Market(R) Donates $25,000, for Midwest Farmers - Hoping to Match an Additional $10,000, via Customer Donations 2Health News:Whole Foods Market(R) Donates $25,000, for Midwest Farmers - Hoping to Match an Additional $10,000, via Customer Donations 3Health News:Meeting Expectations Named to First Annual 'CMI 25' List by Corporate Meetings & Incentives Magazine 2Health News:UVA researchers find important clue to immune infertility 2Health News:New Jersey Physicians Launch New, Statewide Association to Fight for Stronger Voice in Healthcare 2Health News:Medina General Hospital and University Hospitals Agree to Pursue Affiliation 2Health News:David Ward Joins OrthoSynetics(TM) as Western Region Sales Manager 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: